Monthly Archives: May 2013

Turning human stem cells into brain cells sheds light on neural development

Posted: May 3, 2013 at 4:50 am

Public release date: 2-May-2013 [ | E-mail | Share ]

Contact: John Ascenzi Ascenzi@email.chop.edu 267-426-6055 Children's Hospital of Philadelphia

Medical researchers have manipulated human stem cells into producing types of brain cells known to play important roles in neurodevelopmental disorders such as epilepsy, schizophrenia and autism. The new model cell system allows neuroscientists to investigate normal brain development, as well as to identify specific disruptions in biological signals that may contribute to neuropsychiatric diseases.

Scientists from The Children's Hospital of Philadelphia and the Sloan-Kettering Institute for Cancer Research led a study team that described their research in the journal Cell Stem Cell, published online today.

The research harnesses human embryonic stem cells (hESCs), which differentiate into a broad range of different cell types. In the current study, the scientists directed the stem cells into becoming cortical interneuronsa class of brain cells that, by releasing the neurotransmitter GABA, controls electrical firing in brain circuits.

"Interneurons act like an orchestra conductor, directing other excitatory brain cells to fire in synchrony," said study co-leader Stewart A. Anderson, M.D., a research psychiatrist at The Children's Hospital of Philadelphia. "However, when interneurons malfunction, the synchrony is disrupted, and seizures or mental disorders can result."

Anderson and study co-leader Lorenz Studer, M.D., of the Center for Stem Cell Biology at Sloan-Kettering, derived interneurons in a laboratory model that simulates how neurons normally develop in the human forebrain.

"Unlike, say, liver diseases, in which researchers can biopsy a section of a patient's liver, neuroscientists cannot biopsy a living patient's brain tissue," said Anderson. Hence it is important to produce a cell culture model of brain tissue for studying neurological diseases. Significantly, the human-derived cells in the current study also "wire up" in circuits with other types of brain cells taken from mice, when cultured together. Those interactions, Anderson added, allowed the study team to observe cell-to-cell signaling that occurs during forebrain development.

In ongoing studies, Anderson explained, he and colleagues are using their cell model to better define molecular events that occur during brain development. By selectively manipulating genes in the interneurons, the researchers seek to better understand how gene abnormalities may disrupt brain circuitry and give rise to particular diseases. Ultimately, those studies could help inform drug development by identifying molecules that could offer therapeutic targets for more effective treatments of neuropsychiatric diseases.

In addition, Anderson's laboratory is studying interneurons derived from stem cells made from skin samples of patients with chromosome 22q.11.2 deletion syndrome, a genetic disease which has long been studied at The Children's Hospital of Philadelphia. In this multisystem disorder, about one third of patients have autistic spectrum disorders, and a partially overlapping third of patients develop schizophrenia. Investigating the roles of genes and signaling pathways in their model cells may reveal specific genes that are crucial in those patients with this syndrome who have neurodevelopmental problems.

See original here:
Turning human stem cells into brain cells sheds light on neural development

Posted in Stem Cells | Comments Off on Turning human stem cells into brain cells sheds light on neural development

Bone Marrow Stem Cell Transplantation and Gene Therapy for Cystinosis – Video

Posted: May 3, 2013 at 4:48 am


Bone Marrow Stem Cell Transplantation and Gene Therapy for Cystinosis
A presentation by Stephanie Cherqui, PhD, University of California, San Diego at the 2013 Day of Hope Cystinosis Research Foundation Family Conference, Balbo...

By: Natalieswish

See the original post:
Bone Marrow Stem Cell Transplantation and Gene Therapy for Cystinosis - Video

Posted in Gene therapy | Comments Off on Bone Marrow Stem Cell Transplantation and Gene Therapy for Cystinosis – Video

Relumins Launches Day Cream with Multi-functional Benefits of Stem Cell Therapy

Posted: May 3, 2013 at 4:46 am

Asbury Park, NJ (PRWEB) May 02, 2013

Relumins, a brand that is always on the cutting edge of pharmaceutical-grade skincare, has developed a cream that does it all. The Relumins scientists and product engineers, who have access to world-class data and research, have created a TA Stem cell day cream to target signs of skin aging. So what is TA- Stem Cell therapy and how does this wonder cream work?

Relumins unveils the first whitening & aging cream to combine Placental Protein and TA- Stem Cell to actually make your look younger and healthier. The Relumins TA-Stem Cell Therapy day cream uses Biocellact CHAMOMILLA BD a natural anti-aging ingredient extracted from Chamomile flowers, to slow down aging and production of TA-Stem Cells causing a delay in skin wrinkles and dryness. Laboratory tests not only prove that Biocellact CHAMOMILLA BD slows down aging of TA-stem cells but keeps them in vital condition. Keeping the TA-Stem cells in vital condition, with the combination of stimulating collagen, delays new wrinkle formation and allows skin a smoother, firmer, more youthful appearance.

Skin whitening products are often drying to the skin, the new Relumins face cream is the opposite, and it absorbs deep and leaves the skin feeling hydrated and fresh. After a few weeks of use the skin is noticeable different with fine lines lightened. Says Suzzy of Flawless Beauty and Skin

This amazing new formula is designed to whiten skin, and help you achieve a healthy even glow. The active ingredients are nestled in a light micro gel-cream designed to hydrate and deeply absorb into the skin. Having the cream penetrate deep into the skins layers, allows the ingredients to breakdown dark pigments and prevent new pigment formation. Placental Proteins are also used to help revive tired damaged skin as well as stimulate healthy skin repair. The Relumins TA- Stem Cell formula uses not only active ingredients but also UVA/UVB sun protection, which helps prevent premature aging.

Relumins was developed for people worldwide who demanded high quality effective skincare products without filler ingredients and produced in a state of the art facility. Their commitment to their growing international customer base is to offer complete transparency when it comes to products, processes and the ingredients used. The entire Relumins brand is produced in compliance with United States FDA regulations, and in accordance with strict industry and safety guidelines. This skin care brand guarantees the integrity of the ingredients and the compositional makeup of their products, something rare in the marketplace.

The growing Relumins product line targets all skin care needs, including skin whitening, anti-aging, skin brightening, melasma, age spots, acne control & underarm and intimate specialized products, put them at the leading edge of natural skincare, & lifelong beauty. Relumins uses product descriptions that are clear and informative. When describing the product, the ingredients are each defined with specific benefit and health attribute. Directions, warnings, and possible side effects are all clearly listed. No wonder why this product line is already receiving rave international reviews.

See more here:
Relumins Launches Day Cream with Multi-functional Benefits of Stem Cell Therapy

Posted in Cell Therapy | Comments Off on Relumins Launches Day Cream with Multi-functional Benefits of Stem Cell Therapy

Genetics Policy Institute and univerCELLmarket to co-publish 360 – the Free Newsletter Covering Stem Cells and …

Posted: May 2, 2013 at 7:43 pm

PALM BEACH, Fla. & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--

The Genetics Policy Institute (GPI) and univerCELLmarket announced a joint initiative to produce the most comprehensive and timely online news aggregation and distribution service, providing actionable intelligence for the stem cell and regenerative medicine communities.

Expanding the current 360 newsletter published online by univerCELLmarket, the newsletter will be now co-published and distributed with GPI. Bernard Siegel, GPIs founder and executive director, joins Dr. Beverley Vaughan as the co-editor of the publication. GPI and univerCELLmarket maintain free subscription links on their respective web sites.

Bernard Siegel said, It is the aim of GPI to provide the highest quality information to all interested in stem cells and regenerative medicine. We are delighted to partner with univerCELLmarket. Their comprehensive news aggregation service enables users to efficiently research its archived news and records. With this partnership, interested stakeholders who are part of both GPIs and univerCELLmarkets extensive databases, honed over the past decade, will have easy access to news they can use to advance our field.

Dr. Cathy Prescott, respected thought-leader in the business of stem cells and regenerative medicine, and co-founder of univerCELLmarket said, As a result of partnering with GPI, 360 is now the most widely circulated news service in the world dedicated to this field. With this partnership, our combined contacts, which span academia, industry, government, law, ethics, medicine and advocacy will receive the news highlights in their in-box every Monday, with links to all the weeks news on univerCELLmarket.com.

Jeanette Walker, co-founder of univerCELLmarket stated, 360 is popular because it is so comprehensive and in a format that makes it quick and easy to scan. We are delighted to welcome Bernard Siegel to our editorial team as he is a recognized architect of the global stem cell community. Bernie founded GPI, the annual World Stem Cell Summit, the peer-reviewed World Stem Cell Report and is an acknowledged leader of the patient advocacy community.

About Genetics Policy Institute (GPI): GPI is a 501c3 nonprofit foundation with the mission to promote and defend stem cell research and its application in medicine to develop therapeutics and cures for many otherwise intractable diseases and disorders. GPI pursues this mission through production of its flagship annual World Stem Cell Summit, publication of the World Stem Cell Report, special projects, speaking engagements, teaching initiatives and strategic collaborations.

ABOUT univerCELLmarket

Launched in 2010, univerCELLmarket.com is an online, global source of relevant, up-to-date information for everyone interested in the field of stem cells and regenerative medicine. Users can rapidly search 10 directories for a wide range of information including stem cell tools, reagents, banks and therapies as well as manufacturers, professional services, academic centres, networks and societies all searchable by country/State - plus the latest news and upcoming events.

Read the original:
Genetics Policy Institute and univerCELLmarket to co-publish 360 – the Free Newsletter Covering Stem Cells and ...

Posted in Genetics | Comments Off on Genetics Policy Institute and univerCELLmarket to co-publish 360 – the Free Newsletter Covering Stem Cells and …

International Stem Cell Corporation to Present at American Society of Gene and Cell Therapy 16th Annual Meeting

Posted: May 1, 2013 at 7:43 pm

CARLSBAD, CA--(Marketwired - May 1, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced that Dr. Ruslan Semechkin, VP of Research and Development, will present additional data from the primate study of the use of neuronal cells for the treatment of Parkinson's disease at the 16th Annual Meeting of American Society of Gene and Cell Therapy, May 15-18, 2013 at the Salt Palace Convention Center in Salt Lake City, UT.

The results, including more detailed analysis of the safety and functional activity of the cells, will be presented orally at the following session:

Session: Stem Cell Engineering and Therapy Date: Thursday, May 16, 2013 Time: 2:00 PM Room: Ballroom D Title: Cell Replacement Therapy for Parkinson's Disease with Neuronal Cells Derived from Human Parthenogenetic Stem Cells

In addition ISCO will present two posters detailing progress in our pre-clinical metabolic liver disease program and recent achievements with our "safe" iPS cells, induced pluripotent stem cells that do not rely on viral vectors for the genetic reprogramming. The posters will be presented on Thursday, May 16, 2013 between 4:00 pm and 6:00 pm in Exhibit Hall C/D.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Read the rest here:
International Stem Cell Corporation to Present at American Society of Gene and Cell Therapy 16th Annual Meeting

Posted in Cell Therapy | Comments Off on International Stem Cell Corporation to Present at American Society of Gene and Cell Therapy 16th Annual Meeting

Windpipe made from stem cells implanted in 2-year-old girl

Posted: May 1, 2013 at 6:45 pm

CHICAGOA 2-year-old girl born without a windpipe now has a new one grown from her own stem cells, the youngest patient in the world to benefit from the experimental treatment.

Play Video

Hannah Warren has been unable to breathe, eat, drink or swallow on her own since she was born in South Korea in 2010. Until the operation at a central Illinois hospital, she had spent her entire life in a hospital in Seoul. Doctors there told her parents there was no hope and they expected her to die.

The stem cells came from Hannah's bone marrow, extracted with a special needle inserted into her hip bone. They were seeded in a lab onto a plastic scaffold, where it took less than a week for them to multiply and create a new windpipe.

About the size of a 3-inch tube of penne pasta, it was implanted April 9 in a nine-hour procedure.

Early signs indicate the windpipe is working, Hannah's doctors announced Tuesday, although she is still on a ventilator. They believe she will eventually be able to live at home and lead a normal life.

"We feel like she's reborn," said Hannah's father, Darryl Warren.

"They hope that she can do everything that a normal child can do but it's going to take time. This is a brand new road that all of us are on," he said in a telephone interview. "This is her only chance but she's got a fantastic one and an unbelievable one."

Warren choked up and his wife, Lee Young-mi, was teary-eyed at a hospital news conference Tuesday. Hannah did not attend because she is still recovering from the surgery. She developed an infection after the operation but now is acting like a healthy 2-year-old, her doctors said.

Warren said he hopes the family can bring Hannah home for the first time in a month or so. Hannah turns 3 in August.

Read more here:
Windpipe made from stem cells implanted in 2-year-old girl

Posted in Stem Cells | Comments Off on Windpipe made from stem cells implanted in 2-year-old girl

Toddler gets new windpipe from her own stem cells

Posted: May 1, 2013 at 6:45 pm

By Alexandra Sifferlin, TIME.com

updated 9:06 AM EDT, Wed May 1, 2013

Hannah Warren, 2, recovers in a post-op room at the Children's Hospital of Illinois in Peoria.

STORY HIGHLIGHTS

(TIME.com) -- Hannah Warren was born without a trachea but now has one made from plastic fibers and a stew of her own stem cells.

The 2-year-old Korean Canadian has spent every day of her life in intensive care, kept alive by a tube that substituted for the windpipe that was supposed to connect her mouth to her lungs. But nearly a month after her transplant, the toddler is mostly breathing on her own and is responding to doctors and nurses.

The surgery, pioneered by Dr. Paolo Macchiarini, director of the Advanced Center for Translational Regenerative Medicine at the Karolinska Institute in Stockholm, was only the sixth performed in the world, and Hannah was the youngest patient and first to receive the transplant in the United States.

The procedure was approved by the FDA as an experimental operation for patients with very little hope of survival; being born without a trachea is fatal in 99% of cases.

TIME.com: Stem cell therapies may cure chronic conditions

Macchiarini performed the nine-hour operation on April 9 at the Children's Hospital of Illinois after carefully creating the windpipe using stem cells from Hannah's bone marrow that were saturated over a matrix of plastic fibers shaped into a tube.

Originally posted here:
Toddler gets new windpipe from her own stem cells

Posted in Stem Cells | Comments Off on Toddler gets new windpipe from her own stem cells

Girl gets windpipe from her stem cells

Posted: May 1, 2013 at 6:45 pm

By Alexandra Sifferlin, TIME.com

updated 9:06 AM EDT, Wed May 1, 2013

Hannah Warren, 2, recovers in a post-op room at the Children's Hospital of Illinois in Peoria.

STORY HIGHLIGHTS

(TIME.com) -- Hannah Warren was born without a trachea but now has one made from plastic fibers and a stew of her own stem cells.

The 2-year-old Korean Canadian has spent every day of her life in intensive care, kept alive by a tube that substituted for the windpipe that was supposed to connect her mouth to her lungs. But nearly a month after her transplant, the toddler is mostly breathing on her own and is responding to doctors and nurses.

The surgery, pioneered by Dr. Paolo Macchiarini, director of the Advanced Center for Translational Regenerative Medicine at the Karolinska Institute in Stockholm, was only the sixth performed in the world, and Hannah was the youngest patient and first to receive the transplant in the United States.

The procedure was approved by the FDA as an experimental operation for patients with very little hope of survival; being born without a trachea is fatal in 99% of cases.

TIME.com: Stem cell therapies may cure chronic conditions

Macchiarini performed the nine-hour operation on April 9 at the Children's Hospital of Illinois after carefully creating the windpipe using stem cells from Hannah's bone marrow that were saturated over a matrix of plastic fibers shaped into a tube.

Excerpt from:
Girl gets windpipe from her stem cells

Posted in Stem Cells | Comments Off on Girl gets windpipe from her stem cells

Stem cells grow toddler a new windpipe

Posted: May 1, 2013 at 6:45 pm

By Lindsey Tanner

A two-year-old girl born without a windpipe now has a new one grown from her own stem cells, the youngest patient in the world to benefit from the experimental treatment.

Hannah Warren has been unable to breathe, eat, drink or swallow on her own since she was born in South Korea in 2010. Until the operation at a central Illinois hospital, she had spent her entire life in a hospital in Seoul. Doctors there told her parents there was no hope and they expected her to die.

The stem cells came from Hannah's bone marrow, extracted with a special needle inserted into her hip bone. They were seeded in a lab onto a plastic scaffold, where it took less than a week for them to multiply and create a new windpipe.

About the size of a three-inch tube of penne pasta, it was implanted April 9 in a nine-hour procedure.

Early signs indicate the windpipe is working, Hannah's doctors announced Tuesday, although she is still on a ventilator. They believe she will eventually be able to live at home and lead a normal life.

"We feel like she's reborn," said Hannah's father, Darryl Warren.

"They hope that she can do everything that a normal child can do but it's going to take time. This is a brand new road that all of us are on," he said in a telephone interview. "This is her only chance but she's got a fantastic one and an unbelievable one."

Warren choked up and his wife, Lee Young-mi, was teary-eyed at a hospital news conference Tuesday. Hannah did not attend because she is still recovering from the surgery. She developed an infection after the operation but now is acting like a healthy two-year-old, her doctors said.

Warren said he hopes the family can bring Hannah home for the first time in a month or so. Hannah turns three in August.

Go here to see the original:
Stem cells grow toddler a new windpipe

Posted in Stem Cells | Comments Off on Stem cells grow toddler a new windpipe

hESC Research Totals $458 Million out of $1.8 Billion from California Stem Cell Agency

Posted: May 1, 2013 at 5:18 pm

The California stem cell agency today
said that it has awarded $458 million to fund research involving
human embryonic stem cells (hESC) out of a total of $1.8 billion it
has given away during the past eight years.

The amount is of some interest because
the key reason that the agency now exists is the perceived
need in 2004 to fund hESC research in the wake of the Bush
Administration restrictions on federal funding in that area. The
restrictions created a national uproar in the scientific and patient
advocate community, which feared that promising therapies would never
be developed.
The $35 million ballot campaign to
create the agency focused hard on hESC research to the virtual
exclusion of any mention of adult stem cell research. Opposing the
effort were such forces as the anti-abortion movement and the
Catholic church. But this month LifeNews.com carried a mildly
approving item that pointed to the agency's turn towards adult stem
cell research.
When the Obama administration lifted
the Bush restrictions, some questions were raised about the need for
the California effort, which is costing state taxpayers $6 billion,
including interest. But those concerns received little public
attention and quickly died out.
Funding for the agency comes through
state bonds. Cash for new awards is scheduled to run out in 2017. The
agency is looking at developing a public-private effort for thefuture that would need a $50 to $200 million “public investment”
and major private funding.
Amy Adams, CIRM's communications
manager, provided the $458 million figure following publication of
this item yesterday on the California Stem Cell Report.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iQOiBLaIRNc/hesc-research-totals-458-million-out-of.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on hESC Research Totals $458 Million out of $1.8 Billion from California Stem Cell Agency